Courtesy of Benzinga.
MAXIMUS, Inc. (NYSE: MMS) shares traded up nearly 5 percent Thursday following a new Overweight and $63 price target from KeyBanc analyst Jason Twizell.
“We believe MMS can realize upside to consensus EPS estimates given continued growth in the outsourcing of government health programs, including new U.S.specific Medicaid and Health Insurance Exchange opportunities, along with margin maturation for its newer contracts,” Twizell said.
The KeyBanc analyst highlighted the possibility for MAXIMUS to benefit from government-sponsored healthcare programs which continue to transition this kind of management to the private sector. “We believe Medicaid and health insurance exchange-based enrollment growth will provide MMS new and expanded contract opportunities around eligibility, enrollment, provider credentialing, and health assessments,” according to Twizell.
As MAXIMUS shares closed Thursday’s session at $55.37, Twizell’s new price target represented potential upside of about 14 percent.
Latest Ratings for MMS
Date | Firm | Action | From | To |
---|---|---|---|---|
Jun 2016 | KeyBanc | Initiates Coverage on | Overweight | |
May 2016 | Jefferies | Maintains | Buy | |
Apr 2016 | Avondale Partners | Maintains | Market Perform |
View More Analyst Ratings for MMS
View the Latest Analyst Ratings
Posted-In: Analyst Color News Price Target Initiation Analyst Ratings